A
ANI Pharmaceuticals D
D
ANIP
87.390
USD
-2.61
(-2.90%)
مغلق
حجم التداول
40,981
الربح لكل سهم
7
العائد الربحي
-
P/E
-127
حجم السوق
1,895,381,785
الأخبار المقالات
العنوان: ANI Pharmaceuticals
القطاع: Healthcare
الصناعة: Drug Manufacturers - Specialty & Generic
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.